← FDA DRUG APPROVALS

FDA ANDA · ANDA076630

LAMOTRIGINE

Sponsor: PHARMOBEDIENT

APPLICATION
ANDA076630
TYPE
ANDA
ORIGINAL APPROVAL
2009-01-22
LATEST ACTION
2012-03-19
ROUTE
ORAL
DOSAGE FORM
TABLET, FOR SUSPENSION
MARKETING STATUS
Discontinued

Products

LAMOTRIGINEDiscontinued
LAMOTRIGINE 25MG · TABLET, FOR SUSPENSION · ORAL
LAMOTRIGINEDiscontinued
LAMOTRIGINE 5MG · TABLET, FOR SUSPENSION · ORAL

Approval history

2012-03-19Labeling · Supplement 5AP
2011-04-25Labeling · Supplement 4AP
2010-04-27Labeling · Supplement 1AP
2009-01-22OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →